Incidence and impact of brain metastasis in patients with hereditary BRCA1 or BRCA2 mutated invasive breast cancer

17Citations
Citations of this article
22Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Patients with hereditary mutations in BRCA1 or BRCA2 (gBRCA1/2) and breast cancer have distinct tumor biology, and encompass a predilection for brain metastasis (BM). We looked into baseline risk of BMs among gBRCA1/2 patients. Patients with gBRCA1/2, stage I-III invasive breast cancer seen between 2000–2017 with parenchymal BMs. Among gBRCA1 with distant breast cancer recurrence, 34 of 76 (44.7%) were diagnosed with brain metastases compared to 7 of 42 (16.7%) patients with gBRCA2. In the comparator group, 65 of 182 (35.7%) noncarrier triple-negative breast cancer (TNBC) and a distant recurrence experienced BM’s. In a competitive risk analysis using death as a competing factor, the cumulative incidence of BMs was similar between gBRCA1 and noncarrier TNBC patients. The time from primary breast cancer diagnosis to detection of BMs was similar between gBRCA1 and noncarrier TNBC patients (2.4 vs 2.2 years). Survival was poor after BMs (7.8 months for gBRCA1 patients vs. 6.2 months for TNBC noncarriers). Brain was a more common site of initial distant recurrence in gBRCA1 patients versus TNBC noncarriers (26.3% vs. 12.1%). Importantly, the presence of BMs, adversely impacted overall survival across groups (HR 1.68 (95% CI 1.12–2.53), hazard ratio for death if a patient had BMs at the time of initial breast cancer recurrence vs. not). In conclusion, breast cancer BMs is common and is similarly frequent among gBRCA1 and noncarrier patients with recurrent TNBC. Our study highlights the importance of improving the prevention and treatment of BMs in patients with TNBC, gBRCA1 carriers, and noncarriers.

References Powered by Scopus

Olaparib for metastatic breast cancer in patients with a germline BRCA mutation

2441Citations
N/AReaders
Get full text

Talazoparib in patients with advanced breast cancer and a germline BRCA mutation

1564Citations
N/AReaders
Get full text

Adjuvant olaparib for patients with BRCA1- Or BRCA2-mutated breast cancer

1039Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Genome-wide identification and phenotypic characterization of seizure-associated copy number variations in 741,075 individuals

23Citations
N/AReaders
Get full text

The Future of Breast Cancer Research in the Survivorship Field

15Citations
N/AReaders
Get full text

Breast Cancer with Brain Metastasis: Molecular Insights and Clinical Management

13Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Garber, H. R., Raghavendra, A. S., Lehner, M., Qiao, W., Gutierrez-Barrera, A. M., Tripathy, D., … Ibrahim, N. K. (2022). Incidence and impact of brain metastasis in patients with hereditary BRCA1 or BRCA2 mutated invasive breast cancer. Npj Breast Cancer, 8(1). https://doi.org/10.1038/s41523-022-00407-z

Readers over time

‘22‘23‘24‘25036912

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 5

71%

Researcher 2

29%

Readers' Discipline

Tooltip

Medicine and Dentistry 2

29%

Biochemistry, Genetics and Molecular Bi... 2

29%

Computer Science 2

29%

Social Sciences 1

14%

Save time finding and organizing research with Mendeley

Sign up for free
0